Clinical Trial Update: Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial evaluating LP-108 as monotherapy and in combination with azacitidine in adults with relapsed or refractory myelodysplastic syndrom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• LP-108

Snippet

Sponsor: Newave Pharmaceutical Inc | Conditions: AML/MDS, CMML | Phase 1 | Status: COMPLETED